M
Murray Krahn
Researcher at University of Toronto
Publications - 139
Citations - 4100
Murray Krahn is an academic researcher from University of Toronto. The author has contributed to research in topics: Population & Prostate cancer. The author has an hindex of 33, co-authored 139 publications receiving 3480 citations. Previous affiliations of Murray Krahn include Aix-Marseille University & University Health Network.
Papers
More filters
Journal ArticleDOI
Management of neck pain and associated disorders: A clinical practice guideline from the Ontario Protocol for Traffic Injury Management (OPTIMa) Collaboration
Pierre Côté,Jessica J. Wong,Jessica J. Wong,Deborah Sutton,Deborah Sutton,Heather M. Shearer,Heather M. Shearer,Silvano Mior,Silvano Mior,Kristi Randhawa,Kristi Randhawa,Arthur Ameis,Linda J. Carroll,Margareta Nordin,Hainan Yu,Hainan Yu,Gail M. Lindsay,Danielle Southerst,Sharanya Varatharajan,Sharanya Varatharajan,Craig Jacobs,Craig Jacobs,Maja Stupar,Anne Taylor-Vaisey,Gabrielle van der Velde,Douglas P. Gross,Robert J. Brison,Robert J. Brison,Mike Paulden,Carlo Ammendolia,J. David Cassidy,J. David Cassidy,Patrick Loisel,Patrick Loisel,Shawn Marshall,Richard N. Bohay,John Stapleton,Michel Lacerte,Michel Lacerte,Murray Krahn,Roger Salhany +40 more
TL;DR: This guideline is based on recent systematic reviews of high-quality studies and considered the evidence of effectiveness, safety, cost-effectiveness, societal and ethical values, and patient experiences when formulating recommendations.
Journal ArticleDOI
Direct health-care costs attributed to hip fractures among seniors: a matched cohort study
TL;DR: Significant health-care costs, entry into long-term care, and mortality attributed to hip fractures among seniors in Ontario are identified, which may inform health economic analyses and policy decision-making in Canada.
Journal ArticleDOI
Patient and community preferences for outcomes in prostate cancer: implications for clinical policy.
Murray Krahn,Paul Ritvo,Jane Irvine,George Tomlinson,Karen E. Bremner,Andrea Bezjak,John Trachtenberg,Gary Naglie +7 more
TL;DR: Patients’ directly elicited utilities for their own health were higher than community-derived utilities obtained from HUI and QWB administration to the same patients, weakening the argument that prostate cancer screening and treatment should be limited because of severe and debilitative side effects.
Journal ArticleDOI
Emerging Use of Early Health Technology Assessment in Medical Product Development: A Scoping Review of the Literature.
TL;DR: A generally accepted definition of early health technology assessment is suggested to be “all methods used to inform industry and other stakeholders about the potential value of new medical products in development, including methods to quantify and manage uncertainty”.
Journal ArticleDOI
Is there age bias in the treatment of localized prostate carcinoma
Shabbir M.H. Alibhai,Murray Krahn,Murray Krahn,Marsha M. Cohen,Neil Fleshner,George Tomlinson,Gary Naglie +6 more
TL;DR: Treatment recommendations for localized prostate cancer are based on the patient's remaining life expectancy (RLE), which is influenced by age, comorbidity, and tumor grade.